MESO Q4 2019 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+15.7% YoY

Gross Profit

-$60M-3065.4% margin

Operating Income

-$18M-891.9% margin

Net Income

-$21M-1053.7% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+57.5%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$652M

Total Liabilities

$171M

Stockholders' Equity

$481M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+15.7%
Gross Profit	-$60M	-$421,000	-14222.1%
Operating Income	-$18M	-$23M	+23.1%
Net Income	-$21M	-$21M	+0.5%